vorinostat has been researched along with Sarcoma, Ewing in 6 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Sarcoma, Ewing: A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compared with FDA-approved PARP (olaparib) and HDAC (vorinostat) inhibitors, kt-3283 displayed enhanced cytotoxicity in Ewing sarcoma models." | 4.31 | A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma. ( Adomat, H; Bacha, J; Brown, D; Collins, C; Daugaard, M; Ghaidi, F; Joshi, J; Kung, SHY; Lallous, N; Langlands, J; Le Bihan, S; Lizardo, MM; Oo, HZ; Ramos, L; Rezakhanlou, AM; Shen, W; Shyp, T; Sorensen, PH; Truong, S; Zhai, B, 2023) |
| "Several cancers, however, fail to respond to TRAIL's antineoplastic effects." | 1.38 | Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation. ( Beck, JF; Becker, S; Grauel, D; Palani, CD; Sonnemann, J; Trommer, N; Wittig, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ramos, L | 1 |
| Truong, S | 1 |
| Zhai, B | 1 |
| Joshi, J | 1 |
| Ghaidi, F | 1 |
| Lizardo, MM | 1 |
| Shyp, T | 1 |
| Kung, SHY | 1 |
| Rezakhanlou, AM | 1 |
| Oo, HZ | 1 |
| Adomat, H | 1 |
| Le Bihan, S | 1 |
| Collins, C | 1 |
| Bacha, J | 1 |
| Brown, D | 1 |
| Langlands, J | 1 |
| Shen, W | 1 |
| Lallous, N | 1 |
| Sorensen, PH | 1 |
| Daugaard, M | 1 |
| Unland, R | 1 |
| Clemens, D | 1 |
| Heinicke, U | 1 |
| Potratz, JC | 1 |
| Hotfilder, M | 1 |
| Fulda, S | 1 |
| Wardelmann, E | 1 |
| Frühwald, MC | 1 |
| Dirksen, U | 1 |
| Sampson, VB | 1 |
| Vetter, NS | 1 |
| Kamara, DF | 1 |
| Collier, AB | 1 |
| Gresh, RC | 1 |
| Kolb, EA | 1 |
| Pattenden, SG | 1 |
| Simon, JM | 1 |
| Wali, A | 1 |
| Jayakody, CN | 1 |
| Troutman, J | 1 |
| McFadden, AW | 1 |
| Wooten, J | 1 |
| Wood, CC | 1 |
| Frye, SV | 1 |
| Janzen, WP | 1 |
| Davis, IJ | 1 |
| Sonnemann, J | 2 |
| Trommer, N | 1 |
| Becker, S | 1 |
| Wittig, S | 1 |
| Grauel, D | 1 |
| Palani, CD | 2 |
| Beck, JF | 2 |
| Dreyer, L | 1 |
| Hartwig, M | 1 |
| Hong, le TT | 1 |
| Klier, U | 1 |
| Bröker, B | 1 |
| Völker, U | 1 |
6 other studies available for vorinostat and Sarcoma, Ewing
| Article | Year |
|---|---|
A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma.
Topics: Animals; Histone Deacetylase Inhibitors; Humans; Poly(ADP-ribose) Polymerase Inhibitors; Puma; Sarco | 2023 |
Suberoylanilide hydroxamic acid synergistically enhances the antitumor activity of etoposide in Ewing sarcoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Proliferation; Drug Synergism; Etoposide; His | 2015 |
Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Cell Proli | 2015 |
High-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Chromatin; Drug Design; Drug Evaluation, Pr | 2016 |
Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation.
Topics: Apoptosis; Bone Neoplasms; Caspase 8; Cell Line, Tumor; Enzyme Activation; Histone Deacetylase Inhib | 2012 |
Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Butyrates; Caspase 3; Caspase 9; Caspases; Cell Line, | 2007 |